Pneumococcal Resistance and Serotype 19A in Pittsburgh-Area Children With Acute Otitis Media Before and After Introduction of 7-Valent Pneumococcal Polysaccharide Vaccine

2010 ◽  
Vol 50 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Alejandro Hoberman ◽  
Jack L. Paradise ◽  
Nader Shaikh ◽  
David P. Greenberg ◽  
Diana H. Kearney ◽  
...  
PLoS ONE ◽  
2010 ◽  
Vol 5 (7) ◽  
pp. e11638 ◽  
Author(s):  
Silvio D. Brugger ◽  
Pascal Frey ◽  
Suzanne Aebi ◽  
Jason Hinds ◽  
Kathrin Mühlemann

1982 ◽  
Vol 93 (sup386) ◽  
pp. 97-99 ◽  
Author(s):  
Erkki Virolainen ◽  
Jouko Suonpää ◽  
Heikki Puhakka

2010 ◽  
Vol 68 (1) ◽  
pp. 89-92 ◽  
Author(s):  
Damien Dupont ◽  
Farah Mahjoub-Messai ◽  
Martine François ◽  
Catherine Doit ◽  
Patricia Mariani-Kurkdjian ◽  
...  

2005 ◽  
Vol 33 (5) ◽  
pp. 490-500 ◽  
Author(s):  
F Ansaldi ◽  
V Turello ◽  
P Lai ◽  
G Bastone ◽  
S De Luca ◽  
...  

This retrospective cohort study evaluated the effectiveness of a 23-valent pneumococcal polysaccharide vaccine in reducing hospital admission for pneumonia, otitis media and exacerbation of asthma or other syndromes due to Streptococcus pneumoniae in 9170 high-risk individuals. Cohort members were followed from 1 January 1998 to 31 December 2002. With regard to preventing hospitalization due to pneumonia, we observed a decrease in the incidence of 1/10 000 person-months and a reduction in the relative risk of 38% in the vaccinated cohort compared with the non-vaccinated subjects. A decrease in the risk of hospital admission for asthma, acute otitis media, chronic obstructive pulmonary disease and other respiratory infections was also observed in vaccinated compared with non-vaccinated subjects. The specificity of these findings was confirmed by the lack of a protective effect from vaccination for those outcomes, such as hospitalization ‘for all causes’ and ‘other otorhinolaryngological diagnoses’, that were not directly related to pneumococcal disease.


PEDIATRICS ◽  
1984 ◽  
Vol 73 (1) ◽  
pp. 79-81
Author(s):  
V. M. Howie ◽  
John Ploussard ◽  
John L. Sloyer ◽  
James C. Hill

A total of 133 children between 6 and 11 months of age with at least one episode of otitis media were given one of two pneumococcal vaccines. One vaccine contained 25 µm of types 1, 3, 6, 7, 14, 18, 19, and 23 and the other vaccine (control) contained 25 µm of types 2, 4, 5, 8, 9, 12, and 25. Follow-up care of the 65 black infants revealed significantly more otitis media visits in those infants receiving the control vaccine. Among the 68 white infants there was no difference between control and vaccine groups after vaccination.


Sign in / Sign up

Export Citation Format

Share Document